topotecan has been researched along with plx4032 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Gan, J; Gao, Y; Guo, S; Ning, S; Sun, Y; Wang, P; Wang, X; Xiao, Y; Zhang, Y; Zhi, H; Zhou, H | 1 |
2 other study(ies) available for topotecan and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Topics: B7-H1 Antigen; Carcinoma, Hepatocellular; Cytokines; Dasatinib; Humans; Immunosuppression Therapy; Inflammation; Liver Neoplasms; Macrophages; Programmed Cell Death 1 Receptor; Topotecan; Tumor Microenvironment; Vemurafenib | 2022 |